Analysis: I want to thank Dr. Marty Makary for having done a great job...

3mo ago May 12, 2026 at 7:27 PM

I want to thank Dr. Marty Makary for having done a great job at the FDA. So much was accomplished under his leadership. He was a hard worker, who was respected by all, and will go on to have an outstanding career in Medicine. Kyle Diamantas, a very talented person, will be put in the Acting position. President DONALD J. TRUMP

0:00 0:00

AI Analysis

Machine-generated analysis of the post above on 2026-05-13. Not written by the author of the post.

Danger Level

None

Narcissistic State

Grandiose

Authorship

Uncertain

Intensity

15%

Authorship Analysis

Aide-Written

Indicators:

Business-hours timing (~3:27pm ET, within 9am-6pm aide window)
Polished grammar, complete sentences, no typos
Formal personnel-announcement structure typical of staff-drafted posts
Third-person closing 'President DONALD J. TRUMP' signature block — common aide convention
Precise proper names (Marty Makary, Kyle Diamantas) with correct spelling

Psychological Profile

▶ Traits

Big Five:

Extraversion

45%

Agreeableness

55%

Conscientiousness

55%

Neuroticism

15%

Openness

30%

Strongest facet: achievement striving (institutional)

Agency

55%

Communion

40%

Primary drive: status

▶ Narrative

Role: presidential executive / patron · Arc: neutral

chief executive who appoints and replaces officialsarbiter of professional reputation

▶ State

Grandiose State

Trigger: Maintenance (personnel transition at FDA)

Sentiment

+0.55

▶ Clinical

Malignant Narcissism:

Narcissistic

20%

Antisocial

Paranoid

Sadism

Defense Mechanisms:

idealization

Cognitive Complexity:

Complexity

50%

Fact Checks (2)

"Marty Makary served as FDA Commissioner and is departing."

True

Multiple major news outlets — including CNBC, CBS News, CNN, NPR, STAT News, the Washington Post, the Washington Times, TIME, Deseret News, and Fox News — confirmed on May 12, 2026 that Dr. Marty Makary resigned as FDA Commissioner. The departure ended a roughly 13-month tenure that began with his March 2025 confirmation. Reporting indicates the resignation followed sustained pressure from the Trump administration and outside allies, with specific friction over flavored e-cigarette approvals, layoffs of career scientists, and the high-profile departure of cancer regulator Dr. Richard Pazdur (who cited Makary's leadership). HHS Secretary Robert F. Kennedy Jr. issued a statement praising Makary and announcing that the search for a successor was underway. STAT News additionally reported Trump's own remark that Makary 'was having some difficulty.' The trump.fm post in question is dated 2026-05-12, exactly matching the resignation date.

"Kyle Diamantas will be Acting FDA Commissioner."

True

Independently confirmed by STAT News, Newsweek, Fox News, Politico Pro, HCPLive, Medical Device Network, The Hill, Investing.com, and the Center for Science in the Public Interest (CSPI). All sources report that Kyle Diamantas — previously the FDA's Deputy Commissioner for Food, leading the Human Foods Program overseeing nutrition and food safety, and serving as a liaison between FDA, HHS, and the White House — was appointed Acting FDA Commissioner on May 12, 2026 immediately following Makary's resignation. He has a legal/policy background and is expected to guide the agency through the transition while a permanent nominee is selected. The FDA's own organization page for Kyle Diamantas is referenced in search results (though the specific URL returned a 404 at the time of fetch, likely due to an in-progress update reflecting his new role).

Receipts

No contradictions with other posts detected yet.

Analysis

Post type: Formal personnel announcement — departure of FDA Commissioner Marty Makary and naming of Kyle Diamantas as Acting Commissioner.

Authorship

Strong aide-authorship signal. Timing (15:27 ET, business hours), syntactic polish, correctly spelled proper names, and conventional press-release structure all align with staff drafting. The third-person sign-off ("President DONALD J. TRUMP") and stock superlatives ("great job," "outstanding career") are Trump's voice tokens, but the absence of typos, tangents, grievance drift, or emotional reactivity makes purely autograph composition unlikely. Best classified as aide-drafted with presidential approval/light dictation.

Psychological state

Affectively neutral-to-mildly-positive. No narcissistic injury, no rage, no supply-seeking. The post performs the king/executive archetype — bestowing recognition, conferring continuity — rather than the warrior or victim modes that dominate authentic Trump composition.

Level 1 traits (as projected)

Conscientiousness display (orderly succession), agreeableness elevated relative to baseline (praising a departing subordinate without backhanded compliment or grievance).

Level 2 motives

Agency: status conferral and demonstration of administrative control. Mild communion gesture toward Makary.

Level 3 narrative

Subordinate cast in idealized "loyal soldier departing with honor" role. Such public praise often precedes or follows behind-the-scenes friction; the formal warmth may be performative.

Defenses / rhetoric

Mild idealization ("respected by all," "outstanding career"). Standard superlatives. No dehumanization, no propaganda techniques, no reality distortion, no danger indicators.

Clinical significance

None. Baseline executive-announcement register.

Fact Verification

Claim	Verdict	Evidence
"Marty Makary served as FDA Commissioner and is departing."	True	Multiple major news outlets — including CNBC, CBS News, CNN, NPR, STAT News, the Washington Post, the Washington Times, TIME, Deseret News, and Fox News — confirmed on May 12, 2026 that Dr. Marty Makary resigned as FDA Commissioner. The departure ended a roughly 13-month tenure that began with his March 2025 confirmation. Reporting indicates the resignation followed sustained pressure from the Trump administration and outside allies, with specific friction over flavored e-cigarette approvals, layoffs of career scientists, and the high-profile departure of cancer regulator Dr. Richard Pazdur (who cited Makary's leadership). HHS Secretary Robert F. Kennedy Jr. issued a statement praising Makary and announcing that the search for a successor was underway. STAT News additionally reported Trump's own remark that Makary 'was having some difficulty.' The trump.fm post in question is dated 2026-05-12, exactly matching the resignation date.
"Kyle Diamantas will be Acting FDA Commissioner."	True	Independently confirmed by STAT News, Newsweek, Fox News, Politico Pro, HCPLive, Medical Device Network, The Hill, Investing.com, and the Center for Science in the Public Interest (CSPI). All sources report that Kyle Diamantas — previously the FDA's Deputy Commissioner for Food, leading the Human Foods Program overseeing nutrition and food safety, and serving as a liaison between FDA, HHS, and the White House — was appointed Acting FDA Commissioner on May 12, 2026 immediately following Makary's resignation. He has a legal/policy background and is expected to guide the agency through the transition while a permanent nominee is selected. The FDA's own organization page for Kyle Diamantas is referenced in search results (though the specific URL returned a 404 at the time of fetch, likely due to an in-progress update reflecting his new role).

Overall Veracity: 100%